MCL1 and melanoma: To establish the preclinical therapeutic potential of the MCL1 inhibitor S64315 in melanoma, we began our investigation by comparing the efficacy of this agent in both immunocompromised nude mice, which lack functional lymphocyte populations [45], and immunocompetent C57BL/6 J mice.